Last updated: 2026-09-05 03:25:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Imunon, Inc. (IMNN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,57, with a market capitalization of $8,75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,47 to $6,03. This page covers its latest market performance, valuation, price trends and company information.
$8,75M | |
$1,62 | |
$47,61 | |
$1,47 | |
$1,56 | |
33,62K | |
-- | |
-- | |
$6,03 | |
$1,47 | |
-- | |
-- |
Imunon, Inc. (IMNN) last closed at $1,56 as of 2026-09-04 23:32:00, unchanged from the previous close of $1,56.
During the latest regular trading session, IMNN traded between $1,47 and $47,61, with a volume of 33,62K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Imunon, Inc. (IMNN) moved from $1,60 to $1,57, representing a decline of 2,19% ($0,04).
The stock traded between $1,54 and $1,62 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 34,82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2,1%
IMNN is currently trading at $1,57, placing it 2,1% of the way from its 52-week low of $1,47 to its 52-week high of $6,03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Imunon, Inc. (IMNN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.